Tags : cHL

Regulatory

Innovent Biologics and Eli Lilly’s Tyvyt (Sintilimab injection) Receives NMPA

Shots: The approval is based on ORIENT-1 study results assessing Tyvyt in patients with 2L+ Hodgkin’s lymphoma The ORIENT-1 study resulted in effective complete response rates for CT + radiotherapy in patients Tyvyt is an IgG4 mAb, which helps in binding with PD-1 in T cells further blocking PD-L1. In 2015, Innovent Biologics and Eli Lilly collaborated to […]Read More